MedTrace Logo

Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction

NCT07467213 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 5000

Last updated 2026-06-26

No results posted yet for this study

Summary

This study aims to compare the clinical outcomes between routine use of potassium competitive acid blocker (P-CAB) and guideline-directed gastrointestinal (GI) protection strategy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) and being treated with dual antiplatelet therapy (DAPT).

Conditions

  • Acute Myocardial Infarction (AMI)
  • Gastrointestinal Bleeding

Interventions

DRUG

Zastaprazan

Zastaprazan citrate 20mg will be administered orally once daily for gastrointestinal protection according to the study protocol.

DRUG

Proton Pump Inhibitors (PPI)

Guideline-directed gastrointestinal protection using various proton pump inhibitors as determined by the physician.

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-23
Primary Completion
2029-12-31
Completion
2030-12-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07467213 on ClinicalTrials.gov